LUND, SE / ACCESS Newswire / July 17, 2026 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the ...

Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company ...

Alexander B. Olawaiye, MD, shares how relacorilant’s recent approval might change the treatment landscape for ovarian cancer.

A preclinical study finds that combining atovaquone with platelet-derived growth factor receptor inhibitors reduced ovarian cancer tumoroid viability.

The immune system is a major determinant of how patients respond to standard treatments for ovarian cancer, the leading cause of death from gynecological malignancies. But little was known about how ...

Cancer that develops in the ovaries (the egg-producing reproductive organs) is referred to as ovarian cancer. There are three types of ovarian cancer. Each type has differences in how they will ...

A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, ...

Scientists uncover the ovarian cancer cause behind drug resistance and immune therapy failure - here's what the latest 2026 research means for The post From Gut Bacteria to DNA Repair: The Discoveries ...

Translational analyses identify gene expression changes associated with chemotherapy sensitization, anticancer response, and favorable prognosis following Olvi-Vec-primed immunochemotherapy treatment ...